RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA mRNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio Collaboration combines Moderna’s expertise in mRNA technology for rare metabolic disorders with Recordati’s established global rare disease commercial infrastructure Moderna will continue to lead development for mRNA-3927, and if approved, Recordati will lead global commercialization efforts Milan, 29 January 2026 – Recordati today announced that it has entered into a...
RECORDATI ANNUNCIA UNA COLLABORAZIONE STRATEGICA CON MODERNA PER SVILUPPARE E COMMERCIALIZZARE A LIVELLO GLOBALE mRNA-3927 PER IL TRATTAMENTO DELL’ACIDEMIA PROPIONICA mRNA-3927 si inserisce strategicamente nel portafoglio delle malattie rare metaboliche di Recordati La collaborazione unisce l’expertise di Moderna nella tecnologia mRNA per i disturbi metabolicirari con la solida infrastruttura commerciale globale di Recordati nelle malattie rare Moderna continuerà a guidare lo sviluppo di mRNA-3927 e, in caso di approvazione, Recordati guiderà la commercializzazione a livello globale Mila...
After a string of multi-GW contracts and capex announcements, the attractiveness of cloud AI returns remains a hot question amongst investors. In this report, we build a simple framework to answer that question. We estimate Cloud AI returns from CSP disclosures and what we know about large real-world contracts, and benchmark them against what we know about the economics of traditional cloud.
La saison de résultats ne devrait pas apporter de mauvaises surprises concernant la fin 2025 (cf. messages rassurants lors de nos conférences et des pre-close calls) mais les perspectives 2026 devraient rester prudentes face au manque de visibilité. Face à cela, les managements vont à nouveau concentrer leurs efforts sur les leviers internes et l’agilité mais le sentiment sur le secteur pourrait rester fragile à court terme, nous conduisant à maintenir nos estimations prudentes et une approche o...
Earnings season is unlikely to bring any negative surprises for the end of 2025 (cf. the reassuring messages shared during our conferences and pre-close calls). However, the outlook for 2026 is likely to remain cautious given the limited visibility. As a result, management teams are expected to once again concentrate on internal levers and operational agility. Still, sector sentiment should remain fragile in the near term, leading us to maintain our cautious estimates and a stock-picking stance....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.